A detailed history of Kennedy Capital Management, Inc. transactions in Bio Atla, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 31,408 shares of BCAB stock, worth $43,028. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,408
Previous 29,522 6.39%
Holding current value
$43,028
Previous $72,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.88 - $3.46 $3,545 - $6,525
1,886 Added 6.39%
31,408 $108,000
Q4 2023

Feb 14, 2024

SELL
$1.27 - $3.18 $292 - $731
-230 Reduced 0.77%
29,522 $72,000
Q3 2023

Nov 14, 2023

BUY
$1.7 - $3.07 $1,190 - $2,149
700 Added 2.41%
29,752 $50,000
Q2 2023

Aug 14, 2023

BUY
$2.83 - $3.87 $82,217 - $112,431
29,052 New
29,052 $87,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $49.7M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Kennedy Capital Management, Inc. Portfolio

Follow Kennedy Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kennedy Capital Management, Inc. with notifications on news.